Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients (NCT07317154)

🧪 Interventions in This Study

• Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Mayo Clinic in Arizona — Scottsdale, Arizona

📞 Contact the Study Coordinator

Phone: (480) 342-1208

Email: ryan.debra29@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Recurrent Respiratory Papillomatosis

• Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis — Bethesda, Maryland
• Zopa Retreatment and Vector Shedding in Adults With RRP — Atlanta, Georgia
• The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP) — New Haven, Connecticut

Explore by condition: All Recurrent Respiratory Papillomatosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.